Similar articles

• Sirolimus, the first mTOR inhibitor.

  Sánchez-Plumed JA, González Molina M, Alonso A, Arias M. Sánchez-Plumed JA, et al. Nefrologia. 2006;26 Suppl 2:21-32. Nefrologia. 2006. PMID: 17937632 Review. English, Spanish. No abstract available.
• [Immunosuppression in kidney transplantation].

  Legendre C, Zuber J, Anglicheau D, Le Quintrec M, Martinez F, Mamzer-Bruneel MF, Thervet E. Legendre C, et al. Ann Urol (Paris). 2007 Dec;41(6):276-84. doi: 10.1016/j.anuro.2007.08.006. Ann Urol (Paris). 2007. PMID: 18457319 Review. French.
• Clinical evidence on the use of anti-mTOR drugs in renal transplantation.

  Hernández D, Martínez D, Gutiérrez E, López V, Gutiérrez C, García P, Cobelo C, Cabello M, Burgos D, Sola E, González-Molina M. Hernández D, et al. Nefrologia. 2011;31(1):27-34. doi: 10.3265/Nefrologia.pre2010.Jul.10512. Nefrologia. 2011. PMID: 21270910 Review.
• Balancing efficacy and toxicity in kidney-transplant immunosuppression.

  Leichtman AB. Leichtman AB. N Engl J Med. 2007 Dec 20;357(25):2625-7. doi: 10.1056/NEJMe078181. N Engl J Med. 2007. PMID: 18094383 No abstract available.
• Everolimus: efficacy and safety in cardiac transplantation.

  Schaffer SA, Ross HJ. Schaffer SA, et al. Expert Opin Drug Saf. 2010 Sep;9(5):843-54. doi: 10.1517/14740338.2010.511611. Expert Opin Drug Saf. 2010. PMID: 20701555 Review.